We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+21.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$631M
AUM Growth
+$110M
Cap. Flow
+$37M
Cap. Flow %
5.86%
Top 10 Hldgs %
26.93%
Holding
113
New
5
Increased
44
Reduced
29
Closed
9

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$17M
2
GKOS icon
Glaukos
GKOS
+$9.15M
3
BIIB icon
Biogen
BIIB
+$9.05M
4
ELGX
Endologix Inc
ELGX
+$6.78M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.67M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.1M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$11.1M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$5.44M
4
BMY icon
Bristol-Myers Squibb
BMY
+$4.39M
5
CNC icon
Centene
CNC
+$4.18M

Sector Composition

Rank Sector Weight
1 Healthcare 92%
2 Financials 1.18%
3 Technology 0.15%
4 Energy 0.12%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$25.9M 4.1%
1,751,322
+1,051,322
+150% +$17M
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
$19.2M 3.04%
543,347
+268,347
+98% +$6.14M
BIIB icon
3
Biogen
BIIB
$30B
$18.6M 2.94%
68,000
+32,000
+89% +$9.05M
GKOS icon
4
Glaukos
GKOS
$9.83B
$16.7M 2.65%
325,800
+210,000
+181% +$9.15M
AMGN icon
5
Amgen
AMGN
$208B
$16.4M 2.6%
100,000
+35,000
+54% +$5.82M
INCY icon
6
Incyte
INCY
$24.2B
$15.4M 2.43%
115,000
-25,000
-18% -$3.18M
ABMD
7
DELISTED
Abiomed Inc
ABMD
$14.7M 2.32%
117,048
+14,348
+14% +$1.66M
MDT icon
8
Medtronic
MDT
$109B
$14.6M 2.31%
181,115
-34,125
-16% -$2.67M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$78.5B
$14.3M 2.27%
37,000
+10,500
+40% +$3.89M
LLY icon
10
Eli Lilly
LLY
$1.02T
$14.3M 2.26%
170,000
-45,000
-21% -$3.6M
AGN
11
DELISTED
Allergan plc
AGN
$14.1M 2.23%
59,000
-17,000
-22% -$3.96M
GILD icon
12
Gilead Sciences
GILD
$162B
$14.1M 2.23%
206,916
-52,978
-20% -$3.73M
EXEL icon
13
Exelixis
EXEL
$13.3B
$13.7M 2.16%
630,000
-200,000
-24% -$4.07M
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
$13.5M 2.14%
111,702
+20,000
+22% +$2.58M
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.6M 1.84%
715,664
+425,664
+147% +$6.16M
ELGX
16
DELISTED
Endologix Inc
ELGX
$11.6M 1.83%
160,000
+102,500
+178% +$6.78M
CELG
17
DELISTED
Celgene Corp
CELG
$11.6M 1.83%
93,000
– –
PFE icon
18
Pfizer
PFE
$143B
$11.5M 1.82%
353,535
+2,237
+0.6% +$70.5K
NKTR icon
19
Nektar Therapeutics
NKTR
$2.39B
$11M 1.75%
31,333
+4,000
+15% +$899K
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$11.6B
$11M 1.74%
125,000
+75,000
+150% +$6.67M
BMY icon
21
Bristol-Myers Squibb
BMY
$133B
$10.9M 1.73%
201,000
-80,000
-28% -$4.39M
UNH icon
22
UnitedHealth
UNH
$376B
$10.7M 1.69%
65,000
-10,017
-13% -$1.64M
NVRO
23
DELISTED
NEVRO CORP.
NVRO
$10.6M 1.67%
112,614
+23,300
+26% +$2.11M
VRTX icon
24
Vertex Pharmaceuticals
VRTX
$121B
$10.4M 1.65%
95,013
+30,000
+46% +$2.64M
CVS icon
25
CVS Health
CVS
$133B
$10.2M 1.62%
130,000
-10,000
-7% -$798K
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Rhenman & Partners Asset Management held 113 positions worth $631M, up 21% from $522M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management deployed $37M of net new capital in Q1 2017, opening 5 new positions and adding to 44 existing holdings. Its largest new stake was Abbott: 115,000 shares worth $5.11M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $4.39M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2017 buy was Abbott: 115,000 shares worth $5.11M.
  • Rhenman & Partners Asset Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017, an estimated $17M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2017 reduction was Bristol-Myers Squibb, cutting an estimated $4.39M.
  • Rhenman & Partners Asset Management fully exited Teva Pharmaceuticals in Q1 2017, selling an estimated $13.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $631M portfolio in Q1 2017.
  • Rhenman & Partners Asset Management opened 5 new positions and closed 9 in Q1 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 21% quarter-over-quarter to $631M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2017, filed 19 Apr 2017.